Bioelectronics Corp. (Pink Sheets: BIEL)

Dear Reader,

Every once in a while innovation occurs that changes the landscape of the marketplace.  At StockUpTicks, we call it the "better mousetrap."  But what may be even more significant than sheer innovation is when it can be offered at a price point that literally disrupts the existing market. When innovation and cost effectiveness combine, it can be lethal to competitors.

Such may be the case with today's news release from StockUpTicks-featured company Bioelectronics Corp. (Pink Sheets: BIEL).

In fact, the company is so confident about its ActiPatch product, a drug free, anti-inflammatory patch, that its is saying outright that it will disrupt the marketplace.  Take a look at today's news to see why.

Breaking *NEWS* from BioElectronics

Press Release Source: BioElectronics Corporation
Wednesday August 23, 7:00 am ET

FREDERICK, Md, Aug. 23 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the future for its ActiPatch, a drug free, anti-inflammatory patch and the Company's underlying mission of inexpensively helping people reduce pain and inflammation while accelerating healing looks very positive. "Through sales and clinical trials, physicians and patients are recognizing the profound anti-inflammatory therapeutic benefit of ActiPatch," said CEO Andy Whelan.

ActiPatch is currently US FDA cleared for the treatment of edema following blepharoplasty and is also approved in Canada and Europe for the relief of pain in muscosketal conditions. Application has been submitted to the FDA for a new product surgical market clearance. The new clinical trials for heel pain and ankle sprains will be used for US sports medicine and orthopedic over the counter product introductions. "We are optimistic that these new FDA market clearances will facilitate a full 2007 US introduction of our repetitive stress products for heel pain, tennis elbow and carpal tunnel syndrome, as well as wraps for back pain, injured knees, wrist and ankles. "This quarter's retail product introduction in Canada will provide insight into direct-to-consumer sales," said Mr. Whelan.

The Company's sales and marketing to physicians is being rapidly expanded by the addition of new US and Canadian distributors consisting of more than 70 independent sales agents. The Company also relocated its Sales and Customer Service division to new offices.

The Company noted that the recent filing of an SEC SB-2 Registration Statement will allow the Company to obtain listing on the OTCBB has caused some confusion and concern. While the Registration lists 25 million shares being registered, nearly half of the shares are for the potential conversion of the Note Payable and exercise of outstanding warrants at prices up to $.50 per share.

ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com and http://www.stopheelpain.com

Safe Harbor Statement: This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of the company in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

Source: BioElectronics Corporation
aa

About BioElectronics

a

BioElectronics Corporation ("BIEL") designs, manufactures and markets, under the trade name ActiPatchTherapy, a variety of proprietary, drug-free, anti-inflammatory patches that accelerate healing for a broad range of medical indications. BIEL is developing new products for repetitive stress injuries, such as heel pain, carpal tunnel, back pain, sprains and strains and chronic wounds.

The patches are embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day.  The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient-friendly method to reduce soft tissue pain and swelling.

BIEL products deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing and a reduction of pain and swelling allows patients to return to normal activities much sooner.  ActiPatch is FDA approved and affordable.  Instead of paying $100 for a single treatment at a clinic or a hospital, ActiPatch Therapy provides 10 days of treatment for $49.95. 
 

BIEL’s products are a technical breakthrough at a market disruptive price point. The existing U.S. market for ActiPatch Therapy’s suite of products exceeds $6.5 bil. annually and $20 bil. worldwide. BIEL’s advanced technology platform will effectively “change the way people heal”.

• Orthopedic Group, strains, sprains and chronic pain strains, sprains and chronic pain
• Orthopedics, Podiatry, Chiropractic, Occupational/Physical Surgical Group 
• Wound Care Wound Care – acute and chronic acute and chronic
• Hospitals, Long Term Care facilities, plastic surgery and Long Term Care facilities

BIEL products are currently in a 10-store test by Scholl’s Foot Care Centers in the United Kingdom to mount a resume' of clinical evidence of efficacy from practice. Other clinical evidence of efficacy from practicing physicians at medical schools includes: Northwestern University Temple Unisurgeons, theUniversity of Wisconsin, and New York State University. BIEL products are also used by major professional teams including the Baltimore Ravens. BIEL has established the use of ActiPatch by a number of professional sports teams and formed its Sports Medicine Advisory Committee headed by Herm Schneider, Head Trainer Chicago White Sox. This committee includes members from leading professional athletic teams.
a

The Bandage That Heals

a
 

ActiPatch Produces controlled involuntary muscle contractions, helping to speed recovery of normal muscle function, reducing pain, relieving spasms and preventing atrophy. ActiPatch Can Replace More Expensive Therapies Including Bone Growth Stimulators - Muscular Stimulators Ultrasound - Diathermy

a

Recent News  from BioElectronics

Press Release Source: BioElectronics Corporation
Wednesday July 26, 9:00 am ET

FREDERICK, Md., July 26 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that they have signed a distribution agreement with OrthoPro, LLC, Salt Lake City, Utah, for distribution of the ActiPatch(TM) product. OrthoPro LLC will be the exclusive podiatry distributor in the Western States where their 50 sales representatives cover approximately one third of the United States market.

"We are very pleased to have OrthoPro, LLC and its affiliates as the cornerstone of our podiatry sales and distribution. Their dedicated group of professional sales representatives and affiliated podiatrists have a wealth of product knowledge and existing client relationships that will bode well for our future in podiatry," said Andrew J. Whelan, President, BioElectronics Corporation.

Craig Schelling, President of OrthoPro, LLC stated, "Our network of foot and ankle specialists have been extremely pleased with the results of ActiPatch on post operative surgery and inflammatory foot conditions."

To read the complete release and disclaimer, Click Here

Press Release Source: BioElectronics Corporation
Tuesday June 6, 4:13 pm ET

FREDERICK, Md., June 6 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the design for a new retail foot care product has been finalized with ProFoot, Inc. for distribution of the ActiPatch(TM) product in Canada. The new product is expected to be available in retail stores and pharmacies throughout Canada by the end of the summer.

ActiPatch(TM), which is approved by Health Canada, is a drug-free, anti- inflammatory patch for the relief of pain from stress, strains and sprains. Specifically, the ActiPatch will be marketed through the ProFoot(TM) line of foot care products for the relief of such foot conditions as plantar fasciitis, heel spur and arch pain.

"We are pleased that we have completed the all important design phase and will now be moving into the production phase. We value our partnership with ProFoot, Inc. and we are committed to bring this product to the retail market to bring relief to thousands of people who suffer from debilitating foot conditions," said BioElectronics Corporation, CEO Andrew Whelan.

Thomas O'Connor, BioElectronics Corporation's COO further commented, "The speed with which we have been able to design and build a new product speaks highly on our development platform and capabilities. We are looking forward to continuing to build new products for highly respected companies such as ProFoot, Inc. They are a great organization to be associated with and we look forward to making our retail partnership a big success in Canada, Europe and the United States." 

To read the complete release and disclaimer, Click Here

FREDERICK, Md., May 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the company filed a 510(k) Market Clearance application for its new ActiPulse(TM) device with the Food and Drug Administration. ActiPulse(TM) requested indication for use is "the adjunctive use in the palliative treatment of post operative pain and edema in superficial soft tissue."

Andrew J. Whelan, President, stated, "This new device will broaden our sales and market scope into palliative treatment of postoperative edema and pain in superficial soft tissues."

BioElectronics currently manufactures and sells ActiPatch(TM), a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.

This device is currently investigational and not cleared for sale by the FDA, nor is it currently available for purchase in the United States.

To read the complete release and disclaimer, Click Here
>>

Financial Highlights For BioElectronics

a

Recent Trade: 0.16 (06-28-06) 52wk Range: 0.16 - 0.54 Avg Vol (3m): 125,854 Market Cap: 10.18M Float: 5,000,000 (as of 2005-02-14) Fiscal Year End: December 31 State of Incorporation: Maryland

TO CONTACT BIEL

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid five thousand dollars and has been granted one hundred fifty thousand shares by BioElectronics Corp. without restriction from sale for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.